Literature DB >> 418745

Long-term treatment of onchocerciasis in children with low doses of diethylcarbamazine.

J Sowa, S C Sowa.   

Abstract

Two groups of children were treated daily with 12.5 or 25 mg diethylcarbamazine for five months and a further group with 12.5 mg daily for seven weeks; 88 children completed the course. The trial was under constant supervision and ophthalmic and parasitological examinations were carried out at approximately one-month intervals. The acceptability of the drug was poor owing to adverse reactions, but the clinical response to treatment good.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 418745     DOI: 10.1080/00034983.1978.11719282

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  6 in total

Review 1.  Diethylcarbamazine in the treatment of patients with onchocerciasis.

Authors:  K Awadzi; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  Recent developments in the treatment of onchocerciasis.

Authors:  H R Taylor
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

4.  The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis.

Authors:  K Awadzi; K K Adjepon-Yamoah; G Edwards; M L Orme; A M Breckenridge; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

5.  Improving community participation in clinical trials in Ghana; factors to consider.

Authors:  Mark Appeaning; Helen Owusu-Asante; Samuel Kwofie; George Arhin; Andrew Oppong Asamoah; Tawfic Ali; Reginald Roland Amponsah
Journal:  Contemp Clin Trials Commun       Date:  2022-10-03

Review 6.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.